Mantle Cell Lymphoma
📧 Sign up to get email alerts when something new happens for Mantle Cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-04-20Clinical Trial Update: A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma [Phase 2]
A Phase 2 study evaluating tafasitamab plus lenalidomide in mantle cell lymphoma has been terminated, and results were posted on 2025-04-20.
-
CLINICAL_TRIALS trial_result · 2025-04-16Clinical Trial Update: A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas [Phase 1, Phase 2]
Clinical trial update on a Phase I/II study evaluating the safety of autologous CD20 CAR-T cells in relapsed or refractory B-cell non-Hodgki…
-
CLINICAL_TRIALS trial_result · 2025-04-16Clinical Trial Update: Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma [Phase 2]
A Phase 2 clinical trial evaluating the combination of zanubrutinib and rituximab for indolent mantle cell lymphoma is currently recruiting.
-
CLINICAL_TRIALS research · 2025-04-09Clinical Trial Update: Acalabrutinib and Rituximab in Previously Untreated Mantle Cell Lymphoma [Phase 2]
A Phase 2 clinical trial evaluating acalabrutinib plus rituximab as first-line treatment for mantle cell lymphoma is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-04-08Clinical Trial Update: Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma [Phase 2]
A Phase 2 trial evaluating a multi-agent regimen of rituximab, bendamustine hydrochloride, and bortezomib, followed by rituximab and lenalid…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-04-06Clinical Trial Update: Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies [Phase 1]
Phase 1 study evaluating autologous CD19 CAR-T cell therapy SYNCAR-001 with orthogonal IL-2 STK-009 in CD19-positive hematologic malignancie…
-
CLINICAL_TRIALS trial_result · 2025-03-26Clinical Trial Update: Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma [Phase 1]
Phase 1 trial evaluating avelumab, utomilumab, rituximab, ibrutinib, and chemotherapy in patients with relapsed or refractory diffuse large …
-
CLINICAL_TRIALS trial_result · 2025-03-20Clinical Trial Update: Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies [Phase 1, Phase 2]
Acalabrutinib is being evaluated in Phase 1/2 studies in Chinese adults with relapsed or refractory mantle cell lymphoma and chronic lymphoc…
-
CLINICAL_TRIALS trial_result · 2025-03-11Clinical Trial Update: A Non-interventional Study of REVLIMID® (Lenalidomide) Treatment of IPSS Low- or Intermediate-1-risk Myelodysplastic Syndromes Associated With a Deletion 5q or Refractory/Relapsed Mantle Cell Lymphoma in Korea
A completed non-interventional study in Korea assessing lenalidomide (REVLIMID) for IPSS low- or intermediate-1-risk myelodysplastic syndrom…
-
CLINICAL_TRIALS trial_result · 2025-03-07Clinical Trial Update: Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease [Phase 2]
Phase 2 trial evaluating an umbilical cord blood transplant regimen with cyclophosphamide, fludarabine, and total-body irradiation for hemat…
-
CLINICAL_TRIALS trial_result · 2025-03-07Clinical Trial Update: Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies [Phase 2]
Phase 2 trial evaluating reduced-intensity conditioning with fludarabine and melphalan plus total body irradiation for haploidentical stem c…
-
CLINICAL_TRIALS trial_result · 2025-03-05Clinical Trial Update: R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL [Phase 3]
Phase 3 trial comparing R-CHOP plus R-HAD versus R-CHOP followed by maintenance lenalidomide plus rituximab, with an additional maintenance …
-
CLINICAL_TRIALS trial_result · 2025-03-04Clinical Trial Update: A Study to Evaluate the Relationship of Lenalidomide With Tumor Flare Reaction and High Tumor Burden in Participants With Relapsed or Refractory Mantle Cell Lymphoma
A completed trial evaluating the relationship between lenalidomide and tumor flare reactions in participants with relapsed or refractory man…
-
EMA approval · 2025-03-03EMA Authorised: Torisel (temsirolimus) — Pfizer Europe MA EEIG
EMA authorised temsirolimus (Torisel) for renal cell carcinoma and mantle cell lymphoma in the EU, with Pfizer Europe MA EEIG as the marketi…
-
FDA approval · 2025-03-03FDA Approved: LENALIDOMIDE — Original Application (BIOCON PHARMA INC.,)
FDA approved Biocon Pharma Inc.'s lenalidomide as an original ANDA, enabling a generic version of the cancer drug. Indications include multi…
-
CLINICAL_TRIALS trial_result · 2025-02-28Clinical Trial Update: Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant [Phase 2]
Phase 2 trial evaluating ofatumumab with or without bendamustine for mantle cell lymphoma ineligible for autologous stem cell transplant; re…
-
CLINICAL_TRIALS research · 2025-02-28Clinical Trial Update: CD70-targeted immunoPET Imaging of Malignant Cancers [NA]
A clinical trial evaluating CD70-targeted immunoPET imaging in multiple cancers is currently recruiting, including renal cell carcinoma, dif…
-
CLINICAL_TRIALS trial_result · 2025-02-26Clinical Trial Update: Interrogating Biological Signaling Pathway Dysregulations and In Vitro Screening With Personalized Therapies in Relapsed or Refractory Mantle Cell Lymphoma, MCL MATCH Trial [NA]
This update notes the completion of the MCL MATCH trial, which investigates signaling pathway dysregulations and in vitro screening with per…
-
CLINICAL_TRIALS research · 2025-02-24Clinical Trial Update: A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
A post-marketing study evaluating lisocabtagene maraleucel for relapsed/refractory mantle cell lymphoma is currently recruiting.
-
CLINICAL_TRIALS research · 2025-02-24Clinical Trial Update: A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies [Phase 1]
Phase 1 clinical trial update for BP1002 in advanced lymphoid malignancies across several B-cell and T-cell lymphomas; trial status is activ…
-
CLINICAL_TRIALS research · 2025-02-18Clinical Trial Update: Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma [Phase 2]
This clinical trial update reports Phase 2 evaluation of acalabrutinib in combination with R-CHOP as first-line treatment for mantle cell ly…
-
CLINICAL_TRIALS trial_result · 2025-02-12Clinical Trial Update: A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies [Phase 1, Phase 2]
This completed Phase 1/2 trial evaluates the combination of cirmtuzumab and ibrutinib in patients with B-cell lymphoid malignancies, includi…
-
CLINICAL_TRIALS research · 2025-02-07Clinical Trial Update: Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma [Phase 1]
A Phase 1 trial assessing sequential administration of CD19 CAR-NK cells followed by 7x19 CAR-T cells in relapsed/refractory B-cell lymphoma…
-
CLINICAL_TRIALS trial_result · 2025-02-04Clinical Trial Update: Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies [Phase 1]
Phase 1 VENOM trial evaluating venetoclax with obinutuzumab and magrolimab in relapsed and refractory indolent B-cell malignancies has compl…
-
CLINICAL_TRIALS approval · 2025-02-03Clinical Trial Update: An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
The document reports marketing approval of ibrutinib for relapsed or refractory mantle cell lymphoma.